Mark W. Lingen

13.0k total citations · 1 hit paper
175 papers, 7.6k citations indexed

About

Mark W. Lingen is a scholar working on Molecular Biology, Otorhinolaryngology and Oncology. According to data from OpenAlex, Mark W. Lingen has authored 175 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Molecular Biology, 58 papers in Otorhinolaryngology and 49 papers in Oncology. Recurrent topics in Mark W. Lingen's work include Head and Neck Cancer Studies (58 papers), Angiogenesis and VEGF in Cancer (26 papers) and Oral Health Pathology and Treatment (24 papers). Mark W. Lingen is often cited by papers focused on Head and Neck Cancer Studies (58 papers), Angiogenesis and VEGF in Cancer (26 papers) and Oral Health Pathology and Treatment (24 papers). Mark W. Lingen collaborates with scholars based in United States, United Kingdom and Canada. Mark W. Lingen's co-authors include Theodore Karrison, Paul M. Speight, John R. Kalmar, Ezra E.W. Cohen, Peter J. Polverini, Everett E. Vokes, Rifat Hasina, Noël Bouck, Richard C. Jordan and Bayardo Perez‐Ordoñez and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Mark W. Lingen

170 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Critical evaluation of diagnostic aids for the detection of oral cancer

2007 503 citations Mark W. Lingen et al. profile →

Peers

Countries citing papers authored by Mark W. Lingen

Since Specialization

Citations

This map shows the geographic impact of Mark W. Lingen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark W. Lingen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark W. Lingen more than expected).

Fields of papers citing papers by Mark W. Lingen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark W. Lingen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark W. Lingen. The network helps show where Mark W. Lingen may publish in the future.

Co-authorship network of co-authors of Mark W. Lingen

This figure shows the co-authorship network connecting the top 25 collaborators of Mark W. Lingen. A scholar is included among the top collaborators of Mark W. Lingen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark W. Lingen. Mark W. Lingen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Neoadjuvant HPV16-specific arenavirus-based immunotherapy HB-200 plus chemotherapy followed by response-stratified de-intensification in HPV16+ oropharyngeal cancer: TARGET-HPV. 2024 ·Journal of Clinical Oncology ·Ari J. Rosenberg, Aditya Juloori, Evgeny Izumchenko, John Cursio, Zhen Gooi, Elizabeth A. Blair, Mark W. Lingen, Nicole A. Cipriani, Rifat Hasina, (unknown), F. R. Jones, Christopher Plescia, (unknown), (unknown), (unknown), Daniel J. Haraf, Alexander T. Pearson, Everett E. Vokes, Nishant Agrawal	4
2	886P Prospective evaluation of dynamic changes of cell-free HPV-DNA (cfHPV-DNA) in locoregional HPV associated (HPV+) oropharyngeal cancer (OPC) treated with neoadjuvant chemotherapy and response-stratified treatment 2023 ·Annals of Oncology ·Ari J. Rosenberg, Evgeny Izumchenko, Aditya Juloori, Zhen Gooi, Alexander T. Pearson, Ann M. Vannier, Elizabeth A. Blair, (unknown), (unknown), Mark W. Lingen, Nicole A. Cipriani, Rifat Hasina, (unknown), Daniel J. Haraf, Everett E. Vokes, Nishant Agrawal	0
3	Proceedings of the North American Society of Head and Neck Pathology Companion Meeting, New Orleans, LA, March 12, 2023: Oral Cavity Dysplasia: Why Does Histologic Grading Continue to be Contentious? 2023 ·Head and Neck Pathology ·(unknown), Mark W. Lingen	5
4	Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma 2021 ·Cell Reports Medicine ·Jaime Chao, (unknown), Alex Zhavoronkov, Ivan V. Ozerov, (unknown), (unknown), Mark W. Lingen, Evgeny Izumchenko, Peter A. Savage	15
5	The Utility of MDM2 and CDK4 Immunohistochemistry and MDM2 FISH in Craniofacial Osteosarcoma 2020 ·Head and Neck Pathology ·(unknown), Mark W. Lingen, James McElherne, (unknown), Carrie Fitzpatrick, Elizabeth Hyjek, Reza Mostofi, Nicole A. Cipriani	21
6	A History of Innovations in the Diagnosis and Treatment of Oral and Head and Neck Cancer 2019 ·Journal of Dental Research ·Peter J. Polverini, Mark W. Lingen	10
7	Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline 2018 ·Journal of Clinical Oncology ·Carole Fakhry, Christina Lacchetti, Lisa M. Rooper, Richard C. Jordan, Danny Rischin, Erich M. Sturgis, Diana Bell, Mark W. Lingen, (unknown), (unknown), José P. Zevallos, Bayardo Perez‐Ordoñez	166
8	Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck 2017 ·Clinical Cancer Research ·Vassiliki Saloura, (unknown), Makda Zewde, Kazuma Kiyotani, Ryan J. Brisson, Jae‐Hyun Park, Yuji Ikeda, Theodore Vougiouklakis, Riyue Bao, Arun Khattri, Tanguy Y. Seiwert, Nicole A. Cipriani, Mark W. Lingen, Everett E. Vokes, Yusuke Nakamura	20
9	Notch1 Activation or Loss Promotes HPV-Induced Oral Tumorigenesis 2015 ·Cancer Research ·(unknown), Riyue Bao, Pieter Faber, Vytautas P. Bindokas, John Bechill, Mark W. Lingen, Michael T. Spiotto	24
10	AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma 2015 ·Clinical Cancer Research ·Toni M. Brand, Mari Iida, Andrew P. Stein, Kelsey L. Corrigan, (unknown), John P. Coan, (unknown), Harsh Bahrar, (unknown), Bryan P. Bednarz, Sandeep Saha, David T. Yang, (unknown), Mark W. Lingen, Vassiliki Saloura, Victoria Villaflor, Ravi Salgia, Randall J. Kimple, Deric L. Wheeler	89
11	WHSC1 Promotes Oncogenesis through Regulation of NIMA-Related Kinase-7 in Squamous Cell Carcinoma of the Head and Neck 2014 ·Molecular Cancer Research ·Vassiliki Saloura, Hyun‐Soo Cho, Kazuma Kiyotani, Houda Alachkar, Zhixiang Zuo, Makoto Nakakido, Tatsuhiko Tsunoda, Tanguy Y. Seiwert, Mark W. Lingen, Jonathan D. Licht, Yusuke Nakamura, Ryuji Hamamoto	83
12	Brush-based Cytology Screening in the Tonsils and Cervix: There Is a Difference! 2011 ·Cancer Prevention Research ·Mark W. Lingen	25
13	Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer 2011 ·Clinical Cancer Research ·Dylan M. Glubb, Elisa Cerri, (unknown), Wei Zhang, Osman Mirza, Emma E. Thompson, Peixian Chen, Soma Das, Jacek Jassem, Witold Rzyman, Mark W. Lingen, Ravi Salgia, Fred R. Hirsch, Rafał Dziadziuszko, Kurt Ballmer‐Hofer, Federico Innocenti	65
14	Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer 2010 ·Journal of Clinical Oncology ·Ezra E.W. Cohen, Daniel J. Haraf, Rangesh Kunnavakkam, Kerstin Stenson, Elizabeth A. Blair, Bruce Brockstein, Eric P. Lester, Joseph K. Salama, A. Dekker, R. Williams, Mary Ellyn Witt, Tatyana A. Grushko, James J. Dignam, Mark W. Lingen, Olufunmilayo I. Olopade, Everett E. Vokes	64
15	The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma 2009 ·Cancer Research ·Tanguy Y. Seiwert, Ramasamy Jagadeeswaran, Leonardo Faoro, Varalakshmi Janamanchi, Vidya Nallasura, Mohamed El Dinali, Soheil Yala, Rajani Kanteti, Ezra E.W. Cohen, Mark W. Lingen, Leslie E. Martin, Soundararajan Krishnaswamy, Andres J. Klein–Szanto, James G. Christensen, Everett E. Vokes, Ravi Salgia	211
16	VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2 2009 ·Cell Death and Differentiation ·(unknown), Kathleen G. Neiva, Mark W. Lingen, Lee M. Ellis, Jacques E. Nör	158
17	A Feed-Forward Loop Involving Protein Kinase Cα and MicroRNAs Regulates Tumor Cell Cycle 2008 ·Cancer Research ·Ezra E.W. Cohen, Hongyan Zhu, Mark W. Lingen, Leslie E. Martin, Wen‐Liang Kuo, Eugene A. Choi, Masha Kocherginsky, Joel S. Parker, Christine H. Chung, Marsha Rich Rosner	67
18	Protein Kinase Cζ Mediates Epidermal Growth Factor–Induced Growth of Head and Neck Tumor Cells by Regulating Mitogen-Activated Protein Kinase 2006 ·Cancer Research ·Ezra E.W. Cohen, Mark W. Lingen, Bangmin Zhu, Hongyan Zhu, Michael Straza, Carolyn Pierce, Leslie E. Martin, Marsha Rich Rosner	63
19	Protein kinase C Zeta mediates EGF-induced growth of head and neck tumor cells by regulating MAP kinase 2006 ·Cancer Research ·Ezra E.W. Cohen, Mark W. Lingen, Michael Straza, Carolyn Pierce, Bangmin Zhu, Leslie E. Martin, Marsha Rich Rosner	1
20	Morphine-induced angiogenesis is blocked by methylnaltrexone 2006 ·Cancer Research ·Jonathan Moss, (unknown), Mark W. Lingen	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact